Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

5,393 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy of a nelfinavir- and nevirapine-containing salvage regimen.
Sullivan AK, Nelson MR, Shaw A, Moyle GJ, Mandalia S, Gazzard BG, Asboe D. Sullivan AK, et al. Among authors: nelson mr. HIV Clin Trials. 2000 Jul-Aug;1(1):7-12. doi: 10.1310/64pf-wk1q-96y5-axjq. HIV Clin Trials. 2000. PMID: 11590484 Clinical Trial.
New drugs.
Waters L, Nelson MR. Waters L, et al. Among authors: nelson mr. HIV Med. 2005 Jul;6(4):225-31. doi: 10.1111/j.1468-1293.2005.00310.x. HIV Med. 2005. PMID: 16011526 Free article. Review. No abstract available.
Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials.
Nelson M, Arastéh K, Clotet B, Cooper DA, Henry K, Katlama C, Lalezari JP, Lazzarin A, Montaner JS, O'Hearn M, Piliero PJ, Reynes J, Trottier B, Walmsley SL, Cohen C, Eron JJ Jr, Kuritzkes DR, Lange J, Stellbrink HJ, Delfraissy JF, Buss NE, Donatacci L, Wat C, Smiley L, Wilkinson M, Valentine A, Guimaraes D, Demasi R, Chung J, Salgo MP. Nelson M, et al. J Acquir Immune Defic Syndr. 2005 Dec 1;40(4):404-12. doi: 10.1097/01.qai.0000185314.56556.c3. J Acquir Immune Defic Syndr. 2005. PMID: 16280694 Clinical Trial.
Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeks.
Trottier B, Walmsley S, Reynes J, Piliero P, O'Hearn M, Nelson M, Montaner J, Lazzarin A, Lalezari J, Katlama C, Henry K, Cooper D, Clotet B, Arastéh K, Delfraissy JF, Stellbrink HJ, Lange J, Kuritzkes D, Eron JJ Jr, Cohen C, Kinchelow T, Bertasso A, Labriola-Tompkins E, Shikhman A, Atkins B, Bourdeau L, Natale C, Hughes F, Chung J, Guimaraes D, Drobnes C, Bader-Weder S, Demasi R, Smiley L, Salgo MP. Trottier B, et al. Among authors: nelson m. J Acquir Immune Defic Syndr. 2005 Dec 1;40(4):413-21. doi: 10.1097/01.qai.0000185313.48933.2c. J Acquir Immune Defic Syndr. 2005. PMID: 16280695 Clinical Trial.
The use of caspofungin in HIV-infected individuals.
Waters L, Nelson M. Waters L, et al. Among authors: nelson m. Expert Opin Investig Drugs. 2007 Jun;16(6):899-908. doi: 10.1517/13543784.16.6.899. Expert Opin Investig Drugs. 2007. PMID: 17501701 Review.
5,393 results